Articles tagged with Pancreatic Cancer
Researchers discovered that targeting arginase 2, an enzyme involved in nitrogen metabolism, can curb the growth of pancreatic tumors, especially in obese individuals. The study suggests a novel approach to treating this deadly cancer, with potential for improved survival rates and therapeutic windows.
Patients with newly diagnosed cancer face a substantially increased short-term risk of arterial thromboembolism. Lung, gastric, and pancreatic cancers are associated with the highest risk, while advanced disease increases overall tumor burden.
A study of 43 patients with pancreatic ductal adenocarcinoma found two preoperative factors strongly predictive of poor prognosis, regardless of tumor stage. These biomarkers, C-reactive protein/albumin ratio and prognostic nutritional index, may help plan treatment strategies to improve patient outcomes.
Researchers at Tokyo Medical and Dental University identified two microRNAs that can improve pancreatic cancer response to gemcitabine, a common chemotherapy drug. These findings suggest novel combined treatments for this devastating disease. MicroRNA levels can also predict prognosis in pancreatic cancer patients.
Researchers at Cold Spring Harbor Laboratory have discovered an epigenetic factor, FOXA1, that reprograms gene enhancers in cancer cells, allowing them to 'remember' an earlier developmental state and become metastatic. This mechanism is a major breakthrough in understanding the spread of pancreatic cancer.
A new SU2C-Lustgarten Foundation team aims to apply CAR T-cell therapy to pancreatic cancer, a deadly form of cancer with low five-year survival rate. The team will focus on epigenetics and exploring new therapies targeting mesothelin in pancreatic cancer.
Researchers found that inhibiting the partnership between Tregs and dendritic cells might lead to effective immunotherapy for pancreatic cancer. Blocking this relationship may enable the immune system to target pancreatic tumor cells more effectively, potentially slowing tumor growth.
A newly identified biomarker panel correctly detects early pancreatic cancer in human cells, improving the ability to diagnose patients at different stages of their disease. The panel combines plasma thrombospondin-2 with CA19-9 levels for reliable detection of pancreatic cancer, potentially altering treatment outcomes.
The Damon Runyon Cancer Research Foundation awarded $3.1M to five new Clinical Investigators and Continuation Grants to three existing recipients. The winners are conducting groundbreaking research in pancreatic cancer, glioblastoma, and leptomeningeal metastasis.
A combined molecular biology test can accurately identify benign pancreatic lesions, potentially sparing patients from unnecessary cancer screenings and operations. The test uses two proteins to rule out precancer and cancer, with a sensitivity of 95.5% and specificity of 100% for distinguishing between serous cystic neoplasms (SCN) an...
A new study demonstrates the feasibility and safety of HuMab-5B1, an antibody that targets the cancer antigen 19-9, found on pancreatic tumors and other malignancies. The treatment shows promise for better identifying tumors and directing treatment.
Researchers developed 'iExosomes' that target mutant KRAS, a common mutation in pancreatic cancer, to deliver RNAi and suppress tumor growth. The therapy approach was more efficient than traditional methods, offering new hope for treating this aggressive form of cancer.
In a Phase 2 clinical trial, adding an experimental drug to standard chemotherapy improved progression-free survival by four months in patients with metastatic pancreatic cancer and high levels of hyaluronic acid in their tumors. The results suggest the benefit of the treatment is restricted to patients with this specific biomarker.
A new study by researchers at the University of Southern California reveals that reducing glucose-regulated protein GRP78 can halt pancreatic cancer development and prolong survival. The findings suggest that targeting this protein could lead to a novel approach in treating KRAS-mutation related cancers.
Recent studies identified targeted therapies that improved benefits for patients with pancreatic cancer, including one with an ALK gene mutation. The assessment of actionable alterations is now part of routine care at UPMC.
Researchers discovered mutations in gene promoters that affect cell adhesion and axon guidance pathways in pancreatic cancer, providing new insights into its development and progression. These findings could lead to the identification of novel molecular targets for treatment.
Researchers suggest that radiotherapy could have a role in extending the lives of patients with early-stage pancreatic cancer. Studies show that higher doses of radiation are associated with longer survival times. The study analyzed data from over 500 patients and found that those who received higher doses lived significantly longer.
A new study published in the Journal of the American College of Surgeons found that pancreatic cancer patients who travel to academic medical centers for surgery have longer overall survival rates and better quality care. For thyroid cancer patients, traveling also results in more adherence to evidence-based treatment guidelines.
A new study by TGen and HonorHealth Research Institute found a very high rate of tumor shrinkage among patients with advanced pancreatic cancer when adding cisplatin to standard gemcitabine/nab-paclitaxel treatment. The results showed statistically significant improvements in overall response and survival rates.
FAU researchers identified Zeb1 as a key factor that activates embryonic programme, leading to rapid dissemination and metastasis in pancreatic cancer. They also found that blocking Zeb1 reduces metastatic capacity in other tumour types.
Wake Forest Baptist researchers found that MIR506 inhibits malignant cell growth and metastasis in pancreatic cancer cells. The molecule induces autophagy, a process that promotes cancer cell death.
Researchers at NYU Langone Health have uncovered a critical pathway by which pancreatic cancer cells evade the immune system, involving high levels of two proteins - dectin-1 and galectin-9. The study found that blocking this interaction can increase survival in mice with pancreatic tumors.
Australian scientists have discovered a novel strategy to treat pancreatic cancer by softening tumors with Fasudil before chemotherapy, doubling survival time and improving treatment efficacy. The sequential approach also slows cancer spread to other tissues.
Overall cancer death rates have decreased for 11 types of cancer in men and 13 in women between 2010-2014. Five-year survival improved significantly for prostate, kidney, non-Hodgkin lymphoma, and leukemia cancers.
Researchers at the University of Texas M. D. Anderson Cancer Center have identified arginine methyltransferase 1 (PRMT1) as a potential therapeutic target for pancreatic ductal adenocarcinoma (PDAC), a deadly form of pancreatic cancer with limited treatment options. PRMT1 plays a crucial role in tumor development and maintenance, and i...
Researchers at Tel Aviv University find that modifying specific proteins during cell division unleashes a natural killing mechanism that targets rapidly proliferating cancer cells. The discovery may lead to the development of new treatments for aggressive cancers, including pancreatic and triple negative breast cancer.
A network of clinical trials aims to find the right treatment for the right patient, using individual molecular profiles. The project will recruit 658 patients across the UK, with a focus on matching patients with suitable clinical trials already in progress.
A new optical tool uses light scattering spectroscopy to distinguish between pre-cancerous and cancerous pancreatic lesions with high accuracy. The device offers a minimally-invasive means of diagnosis, which could reduce unnecessary surgeries and improve patient outcomes.
Adding two blood-borne proteins, TFPI and tenascin C, to the current biomarker CA-19-9 improves the detection of early-stage pancreatic cancer in three cohorts. The combination shows higher predictive value than the individual biomarkers.
Researchers identified PAK1 as a key player in aggressive tumor growth, fibrosis, and chemotherapy resistance. Targeting PAK1 may increase survival rates for patients with pancreatic cancer.
A team of researchers at CIMA University has identified a new gene, FOSL1, which is critical in the development of lung and pancreatic cancers. Inhibiting this gene has been shown to drastically reduce tumor size in various experimental models.
Death rates from cancer are expected to decline faster in men than in women in Europe in 2017, with men predicted to fall by over 8% and women by around 4%. Lung cancer death rates will rise in women, but overall, fewer women than men will die from cancer.
A new study confirms PAK4's role in enabling pancreatic cancer cells to grow and spread, highlighting potential new targets for therapy. Researchers found a close relationship between PAK4 and the phosphoinositide 3-kinase pathway, which could lead to combination therapies targeting both.
A registry study of over 72,000 styrene-exposed employees found no increased incidence of common cancers such as oesophagus or lung cancer. However, a possible increased risk of myeloid leukaemia and nasal cancer was detected, highlighting the need for further investigation.
Researchers identified a gatekeeper protein SMARCB1 that prevents aggressive pancreatic cancer cells from transitioning into a resistant type. Depletion of SMARCB1 leads to mesenchymal status, a mobile and invasive cell state, making these cells vulnerable to therapies targeting proteostasis.
Researchers at Arizona State University have developed a new diagnostic method for detecting pancreatic cancer early in its development by identifying extracellular vesicles with the surface protein EphA2. This technique shows promise for rapid and sensitive detection of various diseases based on unique EV signatures.
Research found that patients diagnosed with type 2 diabetes are at increased risk of developing pancreatic cancer, particularly within the first year. The study's findings suggest a link between rapid deterioration in diabetes and early detection of pancreatic cancer.
Blocking inflammation after radiation therapy led to improved survival in a mouse model of pancreatic cancer. The study found that a form of inflammation triggered by the tumor in response to treatment helps keep tumor cells alive, and that blocking this inflammation can slow tumor growth and prolong survival.
A new standard of care for pancreatic cancer patients has been established with a combination chemotherapy treatment, doubling five-year survival rates. The treatment, combining gemcitabine and capecitabine, was found to be effective in increasing patient survival by 29% compared to single-drug therapy.
A UK-led clinical trial has successfully prolonged survival for pancreatic cancer patients by at least five years using a combination of chemotherapy drugs. The study found that patients who received this treatment had a 29% five-year survival rate compared to 16% for those on standard treatment.
Cancer mortality in the US declined by 20.1% from 240 to 192 deaths per 100,000 population between 1980 and 2014. Distinct clusters of counties with high cancer mortality rates were found, varying by type of cancer and region.
Cachexia, a condition characterized by weight loss and muscle atrophy in cancer patients, is responsible for over 30% of deaths. Researchers aim to reverse this condition through novel treatments involving febuxostat, beta-blockers, and gut microbiome transplantation.
Researchers at Salk Institute found that pancreatic cancer cells alter their metabolism in response to signals from surrounding stromal cells. Blocking these signals with a drug called JQ1 can slow tumor growth in mice, paving the way for potential new treatments.
Scientists identified collateral lethal vulnerability in pancreatic cancers that can be targeted pharmacologically in certain patient populations. ME3 inhibitors may provide an effective therapy for many cancer patients.
The UK Pancreatic Cancer Research Fund has awarded £9 million in grants to five promising research projects aimed at developing new treatments and diagnostic tools for pancreatic cancer. These projects focus on improving clinical trials, investigating innovative therapies, and understanding the genetic causes of chromosomal instability.
Researchers found PDX1 plays a complex role in pancreatic cancer, maintaining cell identity in normal cells but contributing to growth once tumor forms. Blocking PDX1 may actually make the cancer more aggressive by selecting for MYC-expressing cells.
A Vanderbilt-led study identifies a compound that can reverse the malignant reprogramming of metastatic pancreatic cancer cells. The research found that distant metastases undergo massive epigenetic changes that enable tumor formation, but these changes can be reversed with the inhibition of phosphogluconate dehydrogenase enzyme.
A study found that epigenetic changes, not DNA mutations, drive metastasis in pancreatic cancer cells. Researchers also identified a potential therapeutic target to block tumor formation in lab-grown cancer cells.
A University of Liverpool research team has discovered that tumour-associated macrophages and fibroblasts secrete insulin-like growth factors, which activate a survival signalling pathway in pancreatic cancer cells, making them resistant to chemotherapy. This mechanism is found in 72% of patients, paving the way for new therapeutic tar...
Researchers at the University of Notre Dame have made a groundbreaking discovery that could pave the way for pancreatic cancer treatment. The study reveals that exosomes, tiny vesicles released by supporting cells, can educate cancer cells on how to survive chemotherapy, making the disease resistant to treatment.
Dr. Daniel Von Hoff has been recognized as a 'Giant of Cancer Care' for his pioneering work in gastrointestinal cancer and development of new treatments. He is being honored for his commitment to improving the lives of patients and families affected by cancer.
Pancreatic cancer is expected to become the third leading cause of death from cancer in the EU by 2017. The number of deaths from pancreatic cancer will overtake breast cancer mortality rates in the EU, with 91,500 estimated deaths next year.
TGen researchers discovered that blocking nerve growth factor (NGF) signaling can reduce the potential of pancreatic cancer cells to invade surrounding nerves, leading to pain. The study found that NGF and its receptor TRKA are associated with perineural invasion, a key mechanism in the progression of pancreatic cancer.
Researchers found a specific rearrangement of collagen fibers surrounding tumors associated with early death, which may indicate poorer survival rates. The study suggests that understanding collagen's role in cancer could lead to new therapeutic targets for pancreatic cancer.
Researchers at Kumamoto University have developed a new method to detect pancreatic cancer using blood biomarkers, enabling early-stage diagnosis and improving prognosis. The discovery of insulin-like growth factor binding protein 2 (IGFBP2) and IGFBP3 as promising biomarkers shows promise for screening various types of cancer.
Researchers have discovered that gold nanoparticles can reduce cell proliferation and migration near pancreatic tumors by interrupting cellular communication. This breakthrough could lead to a new type of treatment for the disease, which affects over 53,000 Americans this year.
Studies show that websites for pancreatic cancer treatment differ in their presentation of information. Researchers found that non-profit organizations' websites were more easily understood and recommended by patients. The study suggests that website usability and visuals play a significant role in patient recommendations.
Researchers have discovered that SLC6A14 is overexpressed in pancreatic tumors and cancerous cells, transporting amino acids for cellular metabolism. Blocking SLC6A14 with alpha-methyltryptophan starves pancreatic cancer cells, reducing growth and proliferation
Researchers discovered that pancreatic cancer develops rapidly through a 'big bang' process, where key alterations occur simultaneously. This finding provides new insights into the disease's aggressiveness and may lead to improved diagnostic and therapeutic strategies.
Researchers identified dopamine receptor DRD2 as a key molecule in pancreatic cancer. Blocking the receptor inhibited cancer growth, while its blockade also slowed tumor growth in mice.